Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.73 |
| ▸ | NPC1 | O15118 | 6/20 | 0.67 |
| ▸ | RAB9A | P51151 | 6/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | PKM | P14618 | 1/20 | 0.67 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.54 |
| ▸ | FAAH | O00519 | 3/20 | 0.54 |
| ▸ | STAT3 | P40763 | 1/20 | 0.54 |
| ▸ | STAT1 | P42224 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL71299 | 0.85 | ALDH1A1 (1.00) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL16401825 | 0.84 | CDH1 (0.63) | ALDH1A1NPC1RAB9ASMN1; SMN2KMT2A | |
| SCHEMBL4097265 | 0.82 | ALDH1A1 (0.51) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL368236 | 0.82 | SCD (0.55) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL17789551 | 0.81 | ALDH1A1 (0.73) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL16373714 | 0.81 | ALDH1A1 (0.73) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL6710446 | 0.81 | ALDH1A1 (0.73) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL2678323 | 0.81 | ALDH1A1 (0.73) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL18619869 | 0.81 | ALDH1A1 (0.73) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL10545373 | 0.81 | ALDH1A1 (0.73) | ALDH1A1NPC1RAB9ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626882-A1 | MICROBIOCIDAL TETRAHYDROISOQUINOLINE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-10-08 | — | — | EP | disclosed |
| WO-2024115512-A1 | MICROBIOCIDAL TETRAHYDROISOQUINOLINE DERIVATIVES | SYNGENTA CROP PROTECTION AG (CH) | 2024-06-06 | — | — | WO | disclosed |
| EP-3190109-B1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | UNIV LEUVEN KATH (BE) | 2020-02-19 | — | — | EP | disclosed |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | REMYND (BE) | 2019-02-21 | — | — | US | disclosed |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2018-11-06 | — | — | US | disclosed |
| EP-2655323-B1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LTD (IE) | 2017-12-20 | — | — | EP | disclosed |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2017-08-17 | — | — | US | disclosed |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2017-08-03 | — | — | US | disclosed |
| US-9708286-B2 | Ingenol-3-acylates III and ingenol-3-carbamates | LEO LABORATORIES LIMITED (IE) | 2017-07-18 | — | — | US | disclosed |
| US-8618138-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2013-12-31 | — | — | US | disclosed |
| EP-2655323-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| WO-2012083953-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
| EP-2440550-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-04-18 | — | — | EP | disclosed |
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-04-05 | — | — | US | disclosed |
| WO-2010142801-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-12-16 | — | — | WO | disclosed |
| US-20090069288-A1 | Novel therapeutic compounds | ABBVIE INC. | 2009-03-12 | — | — | US | disclosed |
| WO-2009011850-A2 | NOVEL THERAPEUTIC COMPOUNDS | ABBOTT LABORATORIES (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083475-A1 | INDOLE AMIDE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, NLN | ALDH1A1 2395/4885NPC1 704/4885RAB9A 1779/4885 |
| US-20190054068-A1 | Indole Amide Derivatives and Related Compounds for Use in the Treatment of Neurodegenerative Diseases | SNCA, MAPT, NLN | ALDH1A1 2395/4885NPC1 704/4885RAB9A 1779/4885 |
| US-20170217910-A1 | INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | RXRB, RXRA, RXRG | ALDH1A1 2810/4885NPC1 1253/4885RAB9A 908/4885 |
| US-20080221101-A1 | Calcium receptor modulating agents | CASR, RYR1, RYR2 | ALDH1A1 3089/4885NPC1 1243/4885RAB9A 1512/4885 |
| US-10117850-B2 | Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases | SNCA, MAPT, NLN | ALDH1A1 2404/4885NPC1 651/4885RAB9A 1770/4885 |
| US-20170233379-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | ALDH1A1 3298/4885NPC1 166/4885RAB9A 894/4885 |
| US-20090069288-A1 | Novel therapeutic compounds | MAP3K20, RPS6KB1, MAP3K1 | ALDH1A1 1426/4885NPC1 795/4885RAB9A 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.